SA-012 is an N-acetylgalactosamine (GalNAc) conjugated silencing RNA (siRNA) that targets the mRNA of the PD-L1 gene and is being developed by Suzhou Siran Biotechnology Co. Ltd. for the treatment of chronic hepatitis B (CHB).
Haisco Pharmaceutical Group Co. Ltd. has presented hydroxyacid oxidase 1 (HAOX1; HAO1) inhibitors reported to be useful or the treatment of primary hyperoxaluria type 1 and kidney stones.
Nippon Shinyaku Co. Ltd. has patented discoidin domain-containing receptor 1 (DDR1) inhibitors reported to be useful for the treatment of cancer, diabetic nephropathy, hepatic and pulmonary fibrosis, myelofibrosis, nephritis, osteoarthritis and chronic renal failure.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has synthesized phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer.
Humanwell Healthcare (Group) Co. Ltd. has described sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Schrodinger Inc. and Takeda Pharmaceutical Co. Ltd. have identified 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
Philochem AG has discovered an ultra-high-affinity ACP3 ligand – OncoACP3 – isolated through the screening of DNA-encoded chemical libraries for the potential treatment of prostate cancer.
Syntis Bio Inc. has announced its launch, with a focus on advancing a pipeline of oral therapies engineered for optimization in the small intestine and a portfolio of enzyme replacement therapies to treat orphan metabolic and broad digestive disorders.
Hudson Therapeutics Inc., a U.S. subsidiary of Shaperon Inc., has announced the signing of a memorandum of understanding (MOU) between Shaperon and Dong-A ST Co. Ltd. for the development of nanobody-based new drugs.
RSS
